Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 19/20 | 0.41 |
| ▸ | CTSD | P07339 | 6/20 | 0.41 |
| ▸ | BACE2 | Q9Y5Z0 | 9/20 | 0.37 |
| ▸ | CTSE | P14091 | 2/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6044200 | 0.86 | BACE1 (0.40) | BACE1CTSDBACE2CTSE | |
| SCHEMBL6044246 | 0.86 | BACE1 (0.44) | BACE1CTSDBACE2CTSE | |
| SCHEMBL6044159 | 0.83 | BACE1 (0.40) | BACE1CTSDBACE2 | |
| SCHEMBL6044117 | 0.82 | BACE1 (0.39) | BACE1CTSDBACE2 | |
| SCHEMBL6043689 | 0.82 | BACE1 (0.60) | BACE1CTSDBACE2CTSE | |
| SCHEMBL6044589 | 0.79 | BACE1 (0.39) | BACE1CTSDBACE2 | |
| SCHEMBL6043649 | 0.75 | BACE1 (0.38) | BACE1CTSDBACE2 | |
| SCHEMBL6043906 | 0.75 | BACE1 (0.64) | BACE1CTSDBACE2CTSE | |
| SCHEMBL3351729 | 0.74 | BACE1 (0.59) | BACE1CTSDBACE2 | |
| SCHEMBL3350292 | 0.74 | BACE1 (0.51) | BACE1CTSDBACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060100196-A1 | Substituted amines for the treatment of alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100196-A1 | Substituted amines for the treatment of alzheimer's disease | BACE1, APP, BACE2 | BACE1 1/4885CTSD 292/4885BACE2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.